RayzeBio’s Post

The Heartbreaking Reality: Understanding the Impact of Heart Failure on Lives According to the assessment study by Growth Plus Reports, the global heart failure market was valued at 𝐔𝐒$ 𝟕.𝟐𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏 and is expected to register a revenue 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟐.𝟗𝟎% to reach 𝐔𝐒$ 𝟗.𝟑𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎. Get free sample PDF now: https://lnkd.in/drChh4Wv Top companies:              Boehringer Ingelheim Tenax Therapeutics Novartis Amgen Bristol Myers Squibb Otsuka Pharmaceutical Co., Ltd. Jarvik Heart Incorporated Eli Lilly and Company Bayer (Schweiz) AG AstraZeneca #HeartFailureMarket #CardiacCare #HeartHealth #CardiologyAdvancements #MedicalInnovation #HeartFailureTreatment #CardiacSolutions #HeartFailureAwareness #PatientCare #HeartHealthMatters #CardiacResearch #HeartFailureManagement #HealthcareTechnology #ImprovedOutcomes #CardiovascularHealth

Will the JPM Healthcare Conference set the stage for unprecedented biopharma M&A in 2024? With more than 10 biopharma M&A deals over $1 billion in 2023, the bar is high and investors eagerly expect at least 1 splashy deal. Below the largest 10 biopharma M&A deals of 2023: 1) Bristol Myers $BMY / Karuna $KRTX $14 billion 2) Merck $MRK / Prometheus $RXDX $10.8 billion 3) AbbVie $ABBV / ImmunoGen $IMGN $10.1 billion 4) AbbVie $ABBV / Cerevel $CERE $8.7 billion 5) Astellas / Iveric Bio $ISEE $5.9 billion 6) Eli Lilly $LLY / Dice Therapeutics $DICE $2.4 billion 7) GSK $GSK / Bellus Health $BLU $2 billion 8) AstraZeneca $AZN / CinCor $CINC $1.8 billion 9) Eli Lilly $LLY / Point Biopharma $PNT $1.4 billion 10) Ironwood $IRWD / VectivBio $VECT $1 billion https://lnkd.in/eHT_9CCR

🙄Oh goody, more consolidation within the manufacturer space that will surely reduce the price of the therapies for endocrine and related diseases 🙄 (are you listening @FTC?) But let's just continue to let the hospitals, pharmacies, PBMs, health plans and the broker/consultants take the heat for the price of brand pharmaceuticals in the United States 🙄 .It is well past time for the pharmaceutical manufacturers to explain why the United States pays 333% more, on a net basis, than all other tier-one countries. Reform is desperately needed in the pharmacy ecosystem, but the manufacturers must acknowledge the major part they play in manipulating the system and start actively participating in solutions. SHARx, LLC Pharmaceutical Care Management Association (PCMA) National Association of Chain Drug Stores (NACDS) CVS Health CVS Caremark Navitus Health Solutions Maxor National Pharmacy Services, LLC MedImpact Healthcare Systems, Inc. Express Scripts by Evernorth Optum Optum Rx Drexi Mark Cuban Cost Plus Drug Company, PBC #SHARx #EnoughisEnough #Risingtides #RisingTidesArmy #joinus

Struggling with retention in pediatric studies? Join us at SCOPE, where we'll reveal our groundbreaking partnership designed to tackle pediatric retention challenges in clinical trials! 🌐✨🤝 See you there! Kate Shaw, Marco Lassandro, Eloise Moffett, Oliver Patch Project #innovativetrials #patients #patientaccess #clinicalresearch #pharmaindustry #pharma #pharmaceutical #SCOPE #SCOPE2024 #SCOPEsummit #clinicaltrials.

Underperforming #patientsupport #hubs are an all-too-common problem in the #pharmaceutical industry. Often, manufacturers try to create a hub that patients and prescribers will actually use but fall short in one way or another. Our colleagues at Entrée Health recently published a case study showcasing how a leading oncology company was able to streamline hub communications, spurring engagement and helping patients and HCPs get support easier and faster than ever. If this case study leaves you hungry to learn more, register to watch our FREE webinar, Reimbursement Blueprint: A 4-Step Guide to a Successful Pharmaceutical HUB. https://lnkd.in/gXuAAxbC

In this latest K-Cast series, “Advancing Healthcare With Prescription Drug Therapeutics,” experts offer insights on the future of prescription digital therapeutics (PDTs) and how the landscape might evolve for PDTs over the next 5 years. Watch the series here: https://bit.ly/4dR4oLW #ManagedCare #HealthTech Mahsa Salsabili

Another great option for enrolling patients into the Access4Me program.

Here's a really interesting case study on #patientsupport #hubs:

Industry Impact: Bristol Myers Squibb - Advancing Healthcare Through Innovation Bristol Myers Squibb, a leader in the pharmaceutical industry, continues to advance medical science with its focus on biopharmaceutical products. As one of the largest global pharmaceutical companies, BMS has been instrumental in developing treatments across a range of therapeutic areas, including oncology, cardiovascular, and more. Innovative Treatments: Recent FDA and European Commission approvals for OPDIVO® (nivolumab) US HCP® highlight BMS's commitment to addressing complex health challenges, such as metastatic urothelial carcinoma. Strategic Growth: With significant investments in research and development, Bristol Myers Squibb is poised to impact healthcare outcomes positively, demonstrating robust revenue projections despite fluctuating stock prices. Global Reach: Distributing products worldwide, BMS not only influences the global pharmaceutical market but also enhances patient care across continents. What strategies do you believe are essential for pharmaceutical companies to remain at the forefront of healthcare innovation? Discuss how advancements in medical treatments can shape the future of global health. Disclaimer: This content is for informational purposes only and is not intended as financial advice. #BristolMyersSquibb #HealthcareInnovation #Biopharmaceuticals #Oncology #PharmaceuticalIndustry #MedicalResearch #HealthcareTechnology #Opdivo #FDAApproval #GlobalHealthcare

Underperforming #patientsupport #hubs are an all-too-common problem in the #pharmaceutical industry. Often, manufacturers try to create a hub that patients and prescribers will actually use but fall short in one way or another. This #casestudy showcases how a leading oncology company was able to streamline hub #communications, spurring engagement and helping patients and HCPs get support easier and faster than ever. If this case study leaves you hungry to learn more, register to watch our webinar, Reimbursement Blueprint: A 4-Step Guide to a Successful Pharmaceutical HUB. https://lnkd.in/gXuAAxbC #marketaccess #pharma #biotech Archbow Consulting